GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for TIDE

TIDE

Official Title

Thiazolidinedione Intervention with vitamin D Evaluation (TIDE)

Overview

To evaluate the effect of treatment with thiazolidineiones (TZD) on cardiovascular morbidity and mortality and is expected to be the definitive trial regarding the role of TZDs in the prevention of cardiovascular events in people with type 2 diabetes mellitus

Study Design

Randomized, treatment, open label, parallel group design.

Primary Endpoint

the composite of CV death, non-fatal MI, non-fatal stroke, and significant heart failure; Secondary endpoints: he composite of CV death, nonfatal myocardial infarction, or nonfatal stroke, revascularization, hospitalization for congestive heart failure; total mortality; cardiovascular mortality; major coronary heart disease events, total strokes, microvascular complications of diabetes. All endpoints are adjudicated

Number of Patients

16000

Number of Sites

350

Number of Countries

35

Study Period

2008–2011

Principal Investigator

Hertzel Gerstein

Program Manager

Jackie Bosch

Research Coordinator

Laura Joldersma

Collaborators

GSK

Key Publications

  • Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein H; TIDE Trial Investigators. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4.